CORCEPT THERAPEUTICS INC
In the published model solve dated 2026-Q2, anchored at $110.09, CORCEPT THERAPEUTICS INC (CORT) is priced for today's economics sustained for ~10.1 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Corcept sells one idea twice: block the cortisol receptor to treat hypercortisolism, and block the same receptor to make chemotherapy work better, the second of which the FDA approved in March 2026 as Lifyorli and which oncology guideline writers added to ⟦"Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a preferred regimen in April 2026"⟧. • Selling and administrative expense reached $145.4 million in the three months to March 2026 against $90.7 million in the same quarter a yea
Is CORT overvalued? See what's priced in →
338 institutional managers reported holding CORT in 13F filings for the quarter ended 2026-03-31. Together they hold about 76% of the company; the top 10 hold 50%. 63 opened new positions that quarter. Held by BlackRock, Vanguard Group, Renaissance Technologies, among others. On the short side, 8.6M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (8.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CORT has cut its share count 10.2% over the past five years, spending $214.35M on repurchases. It pays no dividend. Cash returned over the past three years: $43.15M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CORT over the trailing three years: 2026: 2 buys totaling $3.31M. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CORT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +25.0% | -15.2% |
| 2023-11-02 | -9.9% | +0.2% |
| 2024-02-16 | -6.2% | +1.1% |
| 2024-05-02 | +7.5% | +21.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CORT's latest 8-K filings: 2026-07-29 (items 2.02, 7.01, 9.01); 2026-06-17 (items 8.01, 9.01); 2026-06-03 (items 8.01); 2026-05-28 (items 5.02, 5.07, 9.01); 2026-04-30 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.